Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 99,771 shares of Talaris Therapeutics stock in a transaction on Monday, April 17th. The stock was sold at an average price of $2.14, for a total transaction of $213,509.94. Following the transaction, the director now directly owns 2,954,353 shares of the company’s stock, valued at approximately $6,322,315.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Suzanne Ildstad also recently made the following trade(s):

* On Friday, March 17th, Suzanne Ildstad sold 10,436 shares of Talaris Therapeutics stock. The shares were sold at an average price of $2.06, for a total transaction of $21,498.16.

* On Wednesday, March 1st, Suzanne Ildstad sold 29 shares of Talaris Therapeutics stock. The shares were sold at an average price of $2.05, for a total transaction of $59.45.

* On Tuesday, February 21st, Suzanne Ildstad sold 3,500 shares of Talaris Therapeutics stock. The shares were sold at an average price of $2.05, for a total transaction of $7,175.00.

* On Thursday, February 16th, Suzanne Ildstad sold 2,939 shares of Talaris Therapeutics stock. The shares were sold at an average price of $2.06, for a total transaction of $6,054.34.

Shares of NASDAQ:TALS traded down $0.06 during midday trading on Wednesday, hitting $2.12. 83,139 shares of the company’s stock were exchanged, compared to its average volume of 369,462. The stock has a 50 day moving average price of $1.86 and a 200-day moving average price of $1.64. Talaris Therapeutics, Inc. has a 12 month low of $0.89 and a 12 month high of $9.47.

Several research firms have weighed in on TALS. Morgan Stanley decreased their price target on shares of Talaris Therapeutics from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Thursday, February 23rd. HC Wainwright downgraded shares of Talaris Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TALS. JPMorgan Chase & Co. boosted its holdings in  Talaris Therapeutics by 26.3% during the first quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company’s stock worth $146,000 after purchasing an additional 3,090 shares during the last quarter.  Bank of New York Mellon Corp lifted its stake in shares of  Talaris Therapeutics by 11.6% during the 1st quarter. Bank of New York Mellon Corp now owns 59,622 shares of the company’s stock valued at $586,000 after buying an additional 6,198 shares in the last quarter.  BlackRock Inc. lifted its stake in shares of  Talaris Therapeutics by 1.6% during the 1st quarter. BlackRock Inc. now owns 2,433,914 shares of the company’s stock valued at $23,950,000 after buying an additional 38,449 shares in the last quarter.  Charles Schwab Investment Management Inc. increased its holdings in  Talaris Therapeutics by 4.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 52,058 shares of the company’s stock worth $513,000 after acquiring an additional 2,352 shares during the period.  Finally, State Street Corp increased its holdings in  Talaris Therapeutics by 40.6% during the 1st quarter. State Street Corp now owns 261,465 shares of the company’s stock worth $2,573,000 after acquiring an additional 75,463 shares during the period. 65.43% of the stock is currently owned by hedge funds and other institutional investors.

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.